New Treatment for Moderate to Severe Hidradenitis Suppurativa
Part of Infections, Skin clinical trials.
This trial tests a new medicine called SCT650C for people with moderate to severe hidradenitis suppurativa (HS). The goal is to see if it can reduce painful bumps and abscesses better than current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have had hidradenitis suppurativa (HS) for at least 6 months, with bumps or abscesses in at least 2 body areas (like both armpits or one armpit and the groin).
- Your HS must be moderate to severe, meaning you have at least 5 active painful lumps or abscesses.
- You must have tried oral antibiotics for HS and they didn't work well, caused side effects, or you couldn't take them.
- You must not have used certain advanced medications (like Humira, Stelara, or Skyrizi) in the last 2–3 months.
- You must not have a serious infection, active tuberculosis, hepatitis, HIV, or uncontrolled medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called CIT-013 for people with moderate to severe hidradenitis suppurativa (HS) who have not had enough relief from oral antibiotics. The goal is to see if this treatment can reduce painful bumps and abscesses.
This study tests a drug called secukinumab (a type of biologic that targets inflammation) for people with moderate to severe hidradenitis suppurativa (HS). It may be an option if you have tried other treatments and they didn't work well.
This trial is testing an experimental tablet called LT-002-158 in adults with moderate to severe hidradenitis suppurativa (HS) that hasn't improved enough with standard treatments. The goal is to see if it's safe and helps reduce painful lumps and abscesses.
This trial tests a new cream (EVO101) for people with mild to moderate hidradenitis suppurativa (HS), a skin condition causing painful lumps. It aims to see if the cream can reduce the number of lesions. Participants cannot use certain other HS treatments during the study.
This study looks at certain immune cells (called MAIT cells) in the skin of people with hidradenitis suppurativa, a painful skin condition. It will compare samples from people before they start a new biologic treatment, and may help doctors understand how these treatments work.
This study tests a new injected medication (SPY072) for people with moderate to severe hidradenitis suppurativa (HS), a condition causing painful bumps and abscesses. The goal is to see if this treatment can reduce symptoms and improve quality of life.
Hear when a new Hidradenitis Suppurativa (HS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.